Industry and regulators need to collaborate to provide complex generics with the opportunity to build even further on the significant contributions already made by off-patent medicines to savings and access, Christine Baeder, senior vice president and chief operating officer of Teva’s US generics division, tells Generics Bulletin in the first part of an exclusive interview.
Teva’s Christine Baeder sets out her view of complex generics in the US • Source: Teva
When Teva published its economic impact report for 2020 earlier this year, the numbers were a reminder of the significant impact that generic medicines have on healthcare systems worldwide.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
